Business Information
The group's principal activities are to discover and develop novel products for the treatment of diseases through innovative manipulation of the immune system. The group's product pipeline is focused on treatment of cancer and includes therapeutic vaccines, monoclonal antibodies, small molecules and pro-drugs. It's product provenge, a therapeutic vaccine is used for the treatment of prostate cancer and apc8024 is used for the treatment of breast, ovarian and other solid tumors. On 30-Jul-2003, the group acquired corvas international, inc.
|
|
Name |
Title
|
Email
|
| Richard Brewer | Chmn. | N/A | | David Urdal | Dir., Sr. VP, Chief Scientific Officer | N/A | | Gregory Schiffman | Sr. VP, CFO | N/A | | James Caggiano | VP - Sales, Marketing | N/A | | Rick Hamm | Sr. VP - Corporate Development, General Counsel, Sec. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 273 | (91,642) | | 2005 | 210 | (81,547) | | 2004 | 5,035 | (75,240)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
